ORAL CONTRACEPTIVE

摘要

PURPOSE: A triphasic combination progestin/estrogen oral contraceptive regimen for females of child-bearing age provides effective contraception, good cycle control, and minimal side effects while greatly reducing the total contraceptive steroid administered (particularly the estrogenic component) per 28day cycle. CONSTITUTION: A method of contraception is provided, which comprises administering to a female of child bearing age for 23-25 consecutive days, a first phase combination of a progestin at a daily dosage of 40-500 microgram trimegestone, 250 microgram - 4mg dienogest, or 250 microgram - 4mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 microgram ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days, a second phase combination of a progestin at a daily dosage of 40-500 microgram trimegestone, 250 microgram - 4 mg dienogest, or 250 microgram - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 microgram ethinyl estradiol, for 4-15 days, beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days, and a third phase combination of a progestin at a daily dosage of 40-500 microgram trimegestone, 250 microgram - 4 mg dienogest, or 250 microgram - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 microgram ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.